Published in Mult Scler Int on January 22, 2013
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics (2013) 0.92
Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurol (2016) 0.79
Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One (2015) 0.79
Comparison of Antioxidant Status and Vitamin D Levels between Multiple Sclerosis Patients and Healthy Matched Subjects. Mult Scler Int (2014) 0.76
Determinants of stigma in a cohort of hellenic patients suffering from multiple sclerosis: a cross-sectional study. BMC Neurol (2016) 0.75
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. PLoS One (2016) 0.75
Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis. F1000Res (2017) 0.75
Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. Med Sci Monit (2017) 0.75
Autologous Bone Marrow Transplantation in Multiple Sclerosis: Biomarker Relevance for Patient Recruitment and Follow up. J Clin Cell Immunol (2016) 0.75
Reviewing the Unmet Needs of Patients with Multiple Sclerosis. Am Health Drug Benefits (2015) 0.75
Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Mult Scler J Exp Transl Clin (2016) 0.75
Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med (2007) 17.06
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med (2003) 4.86
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature (2010) 3.90
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med (2002) 3.74
Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol (2008) 2.76
Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet (2003) 2.71
B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol (2006) 2.52
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology (2007) 2.47
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol (2009) 2.41
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol (2010) 2.40
Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology (2010) 2.24
Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet (2009) 2.23
Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain (2005) 2.17
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol (2012) 2.01
Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest (2005) 1.95
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A (2004) 1.91
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology (2003) 1.85
Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol (2001) 1.85
Development of biomarkers in multiple sclerosis. Brain (2004) 1.78
Eight-year follow-up study of brain atrophy in patients with MS. Neurology (2002) 1.78
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology (2012) 1.76
Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain (2004) 1.71
Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci U S A (2009) 1.69
Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta (2010) 1.68
Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol (2002) 1.68
Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology (2012) 1.62
Ocular and cervical vestibular evoked myogenic potentials in multiple sclerosis patients. Clin Neurophysiol (2012) 1.61
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology (2009) 1.59
Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol (2009) 1.55
Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol (2006) 1.54
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol (2011) 1.51
Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol (2010) 1.48
Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep Med (2008) 1.47
High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. Acta Neurol Scand (2008) 1.45
Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol (2005) 1.45
Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult Scler (2009) 1.41
Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci (2007) 1.39
Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain (2008) 1.37
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation (2012) 1.29
Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol (2005) 1.28
Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment. Neurology (2012) 1.27
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology (2010) 1.27
Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A (2008) 1.27
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology (2012) 1.27
IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One (2009) 1.25
Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J Exp Med (2003) 1.25
Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis (2009) 1.22
Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol (2008) 1.21
Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis (2008) 1.19
An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A (2007) 1.19
Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand (2009) 1.17
Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol (2005) 1.16
The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Dev Immunol (2010) 1.15
HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol (2007) 1.14
Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One (2008) 1.14
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain (2002) 1.13
Epstein-Barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry (2005) 1.13
Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions. Ann Neurol (2011) 1.13
Interferon-β exacerbates Th17-mediated inflammatory disease. Trends Immunol (2011) 1.10
Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. PLoS One (2012) 1.07
Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol (2010) 1.07
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry (2005) 1.07
CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients. J Autoimmun (2011) 1.05
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol (2003) 1.04
IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci (2005) 1.04
Combined (1)H and (31)P spectroscopy provides new insights into the pathobiochemistry of brain damage in multiple sclerosis. NMR Biomed (2010) 1.04
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology (2004) 1.03
Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol (2010) 1.03
HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch Neurol (1999) 1.02
Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. J Neurol Neurosurg Psychiatry (2000) 1.02
Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler (2006) 1.02
IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuroimmunol (2012) 1.02
Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry (2009) 1.01
Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol (2008) 1.01
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab. Front Cell Neurosci (2012) 1.01
Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol (2002) 0.99
Risk alleles for multiple sclerosis in multiplex families. Neurology (2009) 0.98
Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry (2006) 0.97
Epstein-Barr virus infection of human brain microvessel endothelial cells: a novel role in multiple sclerosis. J Neuroimmunol (2010) 0.96
Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler (2006) 0.95
Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology (2007) 0.95
B cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients. J Immunol (2011) 0.94
Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflammation (2011) 0.94
Investigating axonal damage in multiple sclerosis by diffusion tensor spectroscopy. J Neurosci (2012) 0.94
Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. Neuroimage (2012) 0.92
Comparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients. Mult Scler (2010) 0.91
HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol (2007) 0.91
Cognitive and cortical plasticity deficits correlate with altered amyloid-β CSF levels in multiple sclerosis. Neuropsychopharmacology (2010) 0.90
Myelin basic protein induces inflammatory mediators from primary human endothelial cells and blood-brain barrier disruption: implications for the pathogenesis of multiple sclerosis. Neuropathol Appl Neurobiol (2013) 0.90
Brain endothelial barrier passage by monocytes is controlled by the endothelin system. J Neurochem (2011) 0.89
Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. Mult Scler (2010) 0.89
Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol (2002) 0.89
Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid-phase ELISA. Eur J Immunol (2007) 0.89
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis. J Neuroimmunol (2012) 0.88
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment? Curr Opin Neurol (2012) 0.88
Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis. Neurology (2012) 0.88
Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism. J Neurol Sci (2003) 1.44
Novel mutations and repeated findings of mutations in familial Alzheimer disease. Neurogenetics (2005) 1.07
Dementia as presenting symptom of primary hyperparathyroidism: favourable outcome after surgery. Clin Neurol Neurosurg (2008) 0.98
The impact of comorbidity and other clinical and sociodemographic factors on health-related quality of life in Greek patients with Parkinson's disease. Aging Ment Health (2011) 0.79
Derived Trail Making Test indices: demographics and cognitive background variables across the adult life span. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2015) 0.77
Spastic paretic hemifacial contracture (SPHC) in a patient with multiple sclerosis. A clinical, EMG and neuroimaging study. Neurophysiol Clin (2004) 0.77
Detection of Chlamydia pneumoniae in the cerebrospinal fluid of patients with multiple sclerosis by combination of cell culture and PCR: no evidence for possible association. Mol Diagn (2003) 0.75
Solid-phase synthesis of a biotin derivative and its application to the development of anti-biotin antibodies. Appl Biochem Biotechnol (2009) 0.75